• Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies americanpharmaceuticalreview
    September 03, 2018
    Pfizer announced it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label extension study (B5161004).
PharmaSources Customer Service